Murphy Canyon Acquisition Corp. (NASDAQ:MURF) announced this afternoon that its special meeting, scheduled for September 13, has been postponed to September 20 at 10:00 a.m., marking the SPAC’s second postponement.
As a result of this change, Murphy Canyon has also extended the redemption deadline for holders of its common stock to 5:00 p.m. ET, on September 18.
At the meeting, MURF stockholders will be asked to vote on a proposal to approve its $700.5 million business combination with drug developer Conduit Pharmaceuticals.
Murphy Canyon inked the deal with Conduit in November 2022. The SPAC originally brought $136 million into the deal from its trust, but saw 83.46% of this redeemed during a January extension meeting, leaving it with $22.6 million post-vote. It has supplemented this with a $27 million PIPE at $10 per share including both new and existing investors.
London-based Conduit is working to develop a range of treatments licensed from AstraZeneca (NASDAQ:AZN) with the aim of exiting these assets following the completion of Phase II trials.
The combined company is expected to trade on the Nasdaq under the symbol “CDT” once the deal is completed.
Launch Two (NASDAQ:LPBBU) has filed for a $200 million IPO that shows how the market has shifted for new issuance since its sister SPAC Launch One (NASDAQ:LPAAU) filed just over a month ago. Both SPACs are underwritten by Cantor Fitzgerald and seeking nominally the same raise at IPO, but Launch Two is overfunding its trust...
FTAC Emerald (NASDAQ:EMLD) has entered into a definitive agreement to combine with crypto fintech firm Fold at an enterprise value of $381 million. Phoenix, Arizona-based Fold provides digital banking services backed by a treasury of Bitcoin that includes FDIC-secured checking accounts as well Bitcoin trading and awards. The combined company is expected to trade on...
At the SPAC of Dawn Dealmakers remain confident that AI is going to play a big role in their M&A processes, but feel unprepared for some the changes, according to a new survey of 225 corporate and 75 private equity transactions professionals. SS&C subsidiary Mergermarket generated the report that found more than half of respondents...
Trailblazer Merger I (NASDAQ:TBMC) has entered into a definitive agreement to combine with data intelligence firm Cyabra at an enterprise value of $70 million. Tel Aviv-based Cyabra provides tools to corporations and governments to identify fake accounts and combat social media disinformation. The combined company is expected to trade on the Nasdaq once the deal...
Chain Bridge I (NASDAQ:CBRG) has entered into a definitive agreement to combine with cannabinoid pharmaceuticals firm Phytanix Bio at a pre-deal valuation of $58 million. Santa Barbara, California-based Phytanix is working to develop bladder and seizure treatments using cannabis-based substances. The combined company is expected to trade on the Nasdaq under the symbol “PHYX” once...